教室紹介About Us
沿革と概要
血液内科学講座は、内科学の一部門として1981年4月に開設された血液・呼吸器内科学講座（第三内科）を起源とします。初代教授である三好勇夫先生は、現在成人T細胞性白血病（ATL）として知られる白血病細胞の新培養法を考案、世界初のATL細胞株を樹立し、HTLV-Iウイルス発見に道を開きました。内科を基礎から臨床まで幅広く理解するコンセプトは、二代教授の田口博國教授へと引き継がれてゆきます。血液・呼吸器内科（第三内科）の医局員は概ね20人程度と他大学と変らないものでしたが、2010年代末には血液内科医が 2名にまで減少しました。
医学・医療上の社会的要請から 2019年に血液内科学講座が開設されました。
- 1981年
- 高知医科大学 血液・呼吸器内科学講座（第三内科）開設
- 1982年
- 三好勇夫教授就任
- 1998年
- 田口博國教授就任
- 2007年
- 横山彰仁教授就任
- 2019年
- 高知大学医学部 血液内科学講座開設
初代 小島研介教授就任
- 旧第三内科（1994年）
- 三好勇夫名誉教授と小島研介教授
.
研究と理念
血液疾患の基礎・臨床研究によって、原因、病態の究明から治療法の改良･開発まで、一連のシークエンスとして血液疾患を理解したいと考えています。その具体的な実績として論文業績も公開しています。
In 2019, the Department of Hematology is newly established within the Kochi University, as a dynamic center for patient care, basic and translational research, and teaching in the field of benign and malignant hematology. The Department of Hematology is led by professor Kensuke Kojima, who is a respected hematologist and a pioneer in bench-to-bedside translation of novel cancer therapeutics primarily targeting p53 signaling. His research papers have been cited in >3,500 papers, mainly in the field of cancer therapeutics, suggesting a critical impact on translational research in hematology/oncology. Professor Kojima believes that case reports should add valuable information to our medical knowledge in the current era of evidence-based practice, and has continuously encouraged young physicians to write academic papers, leading to >65 published case reports. Since productive opportunities in hematology require engagement in collaborative global investigation, we are working with world-class universities and hospitals, especially with the University of Texas MD Anderson Cancer Center.
Our department originates from the third Department of Internal Medicine, which was founded in 1981. The first professor Isao Miyoshi is one of the highly respected researchers on Human T-cell leukemia virus type I (HTLV-I), which is now established as a causative agent of adult T-cell leukemia/lymphoma (ATL). The linkage between ATL and HTLV-I was proven by Dr. Miyoshi and his colleagues, demonstrating the presence of an antibody against HTLV-I in patient sera.
We continue to pursue our mission to provide state-of-the-art patient care and comprehensive education to students, trainees and hematologists through medical research, with perseverance and vigor.
Our department originates from the third Department of Internal Medicine, which was founded in 1981. The first professor Isao Miyoshi is one of the highly respected researchers on Human T-cell leukemia virus type I (HTLV-I), which is now established as a causative agent of adult T-cell leukemia/lymphoma (ATL). The linkage between ATL and HTLV-I was proven by Dr. Miyoshi and his colleagues, demonstrating the presence of an antibody against HTLV-I in patient sera.
We continue to pursue our mission to provide state-of-the-art patient care and comprehensive education to students, trainees and hematologists through medical research, with perseverance and vigor.
.
業績
高知大学血液内科（2019年〜）の業績の一部です。業績は日々積み上がっておりますので、最新版については医局員紹介・小島研介教授のページ最下部にある業績（英語版）をご参照ください。
英文原著（2019~. 抜粋）
1. Ureshino H, Kusaba K, Kidoguchi K, Sano H, Nishioka A, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Sueoka E, Kimura S. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma. Ann Hematol. 2019; 98:465-471.
2. Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, Nakao T, Kanda Y, Kosugi N, Kosugi H, Kumagai T, Harada H, Shikami M, Maeda Y, Sakura T, Inokuchi K, Saito A, Nawa Y, Ogasawara M, Nishida J, Kondo T, Yoshida C, Kuroda H, Tabe Y, Maeda Y, Imajo K, Kojima K, Morita S, Komukai S, Kawaguchi A, Sakamoto J, Kimura S. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int J Clin Oncol. 2019; 24:445-453.
3. Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell. 2019; 35:721-737.
4. Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, Allen JE, Oster W, Stogniew M, Ishizawa J, Andreeff M. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia. 2019;33:2805-2816.
5. Okamoto S, Ureshino H, Kidoguchi K, Kusaba K, Kizuka-Sano H, Sano H, Nishioka A, Yamaguchi K, Kamachi K, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Kawaguchi A, Sueoka E, Kimura S. Clinical impact of the CONUT score in patients with multiple myeloma. Ann Hematol. 2020;99:113-119.
6. Watanabe T, Yamashita S, Ureshino H, Kamachi K, Kurahashi Y, Fukuda-Kurahashi Y, Yoshida N, Hattori N, Nakamura H, Sato A, Kawaguchi A, Sueoka-Aragane N, Kojima K, Okada S, Ushijima T, Kimura S, Sueoka E. Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis using the new oral demethylating agent OR-2100. Blood. 2020; 36:871-884.
7. Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. Cancer Sci. 2021;112:1943-1954.
8. Nishida Y, Zhao R, Heese LE, Akiyama H, Patel S, Jaeger AM, Jacamo RO, Kojima K, Ma MCJ, Ruvolo VR, Chachad D, Devine W, Lindquist S, Davis RE, Porco JA Jr, Whitesell L, Andreeff M, Ishizawa J. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia 2021;35:2469-2481.
9. Nishimori T, Higuchi T, Hashida Y, Ujihara T, Taniguchi A, Ogasawara F, Kitamura N, Murakami I, Kojima K, Daibata M. Development of a novel cell line-derived xenograft model of primary herpesvirus 8-unrelated effusion large B-cell lymphoma and antitumor activity of birabresib in vitro and in vivo. Cancer Med. 2021;10:8976-8987.
10. Ogasawara F, Higuchi T, Nishimori T, Hashida Y, Kojima K, Daibata M. Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8-unrelated effusion large B-cell lymphoma in vivo. J Cell Mol Med. 2022;26:5580-5589.
11. Ogasawara F, Yoshida S, Yamane M, Takamatsu K, Arakawa Y, Nishida Y, Komatsu M, Yokoyama A, Yamagishi Y, Kojima K. COVID-19 Cluster in the Hematology/Respirology Ward of a University Hospital during the Seventh Wave of the SARS-CoV-2 Pandemic in Japan: A Descriptive Study. Intern Med. 2023 May 1;62(9):1265-1271.
12. Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Kojima K, Nakamura Y, Fukuhara S, Izutsu K, Abutani H, Yamauchi N, Yuda J, Minami Y; All HM-SCREEN-Japan 01 investigators. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. Cancer Sci. 2023 114:2098-2108.
13. Kurayoshi K, Takase Y, Ueno M, Ohta K, Fuse K, Ikeda S, Watanabe T, Nishida Y, Horike SI, Hosomichi K, Ishikawa Y, Tadokoro Y, Kobayashi M, Kasahara A, Jing Y, Shoulkamy MI, Meguro-Horike M, Kojima K, Kiyoi H, Sugiyama H, Nagase H, Tajima A, Hirao A. Targeting cis-regulatory elements of FOXO family is a novel therapeutic strategy for induction of leukemia cell differentiation. Cell Death Dis. 2023;14:642.
14. Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023;9(48):eadh1436.
15. Egawa Y, Higuchi T, Hashida Y, Ueno K, Kojima K, Daibata M*. Novel paired CD13-negative (MT-50.1) and CD13-positive (MT-50.4) HTLV-1-infected T-cell lines with differential regulatory T cell-like activity. Sci Rep. 2024;14:12549.
16. Kojima K, Watanabe S, Takeuchi A, Kunisawa N, Yoshida S. BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL. J Clin Exp Hematop. 2025;65:174-179.
17. Kojima K, Tsuge N, Yoshida S, Umebara D, Nishida Y, Miyazaki S, Asagiri T. Myelodysplastic neoplasms with unbalanced whole-arm translocation der(5;19)(p10;q10): association with double-hit TP53 mutations. Int J Hematol, in press.
18. Shah NN, Zinzani PL, Wang ML, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss BJ, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve M, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada PB, Cheah CY. Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study. Blood Adv, in press.
英文総説（2019~）
Kojima K, Burger JA. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. J Clin Exp Hematop. 2020; 60:130-137.
英文症例報告（2019~. 抜粋）
1. Kidoguchi K, Yoshimura M, Kojima K, Ureshino H, Egashira R, Yokoo M, Kai K, Egashira Y, Ohshima K, Ando T, Kimura S. Oral ulceration: an unusual manifestation of lymphomatoid granulomatosis. Ann Hematol. 2019;98:1305-1307.
2. Yokoo M, Kojima K, Sano H, Kai K, Arakawa F, Ohshima K, Matsunaga T, Kimura S. Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy. Ann Hematol. 2019;98:1501-1503.
3. Kidoguchi K, Kojima K, Seki R, Nagafuji K, Ohshima K, Kimura S. Is clinicopathological distinction of mucosa-associated lymphoid tissue lymphoma from Waldenström macroglobulinemia essential in MYD88 L265P mutation-positive cases? Int J Hematol. 2019;109:247-248.
4. Kamachi K, Kubota Y, Nagaie T, Yamaguchi Y, Ogusu S, Kidoguchi K, Kusaba K, Kizuka-Sano H, Nishioka A, Yoshimura M, Yokoo M, Ando T, Kai K, Kojima K, Ohshima K, Sueoka E, Kimura S. Primary chest wall MYC/BCL6 double-hit lymphoma with t(3;7)(q27;p12) and t(8;14)(q24;q32) translocations. Intern Med. 2019; 58:2073-2077.
5. Kidoguchi K, Kojima K, Yokoo M, Kimura S. BCR-ABL1- and CBFB-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis. Ann Hematol. 2019;98:2461-2462.
6. Kidoguchi K, Kubota Y, Kusaba K, Kizuka-Sano H, Yamaguchi K, Nishioka A, Yokoo M, Ando T, Kojima K, Kimura S. Severe infusion reaction, anti-rituximab antibodies and lymphoma. QJM. 2020;113:273-274.
7. Ogasawara F, Nakatani Y, Kojima K. Superior vena cava lymphoma. Intern Med. 2020;59:1231.
8. Fujita M, Kamachi K, Yokoo M, Kidoguchi K, Kusaba K, Kizuka-Sano H, Yamaguchi K, Nishioka A, Yoshimura M, Kubota Y, Ando T, Kojima K, Kimura S. Accelerated Phase of Atypical Chronic Myeloid Leukemia with Severe Disseminated Intravascular Coagulation at Initial Presentation. Intern Med. 2020;59:1549-1553.
9. Ando T, Sano H, Yokoo M, Kusaba K, Kidoguchi K, Yamaguchi K, Katsuya H, Yoshihara S, Kubota Y, Kojima K, Kimura S. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor. Int J Hematol. 2020;112:249-253.
10. Saeki K, Nakamura M, Kojima K. Primary pulmonary diffuse large B-cell lymphoma presenting as bulky bilateral lung tumors. Ann Hematol. 2021;100:577-578.
11. Nakamura M, Saeki K, Egashira R, Egashira Y, Kojima K. Gastric emphysema in chemosensitive gastric diffuse large B cell lymphoma. Ann Hematol. 2020;99:2457-2458.
12. Kamachi K, Ando T, Tsuruoka N, Hashiguchi M, Kidoguchi K, Kusaba K, Sano H, Yamaguchi K, Nishioka A, Yoshimura M, Yokoo M, Kubota Y, Kojima K, Kimura S. Successful Anti-TNF-alpha Therapy for Crohn's Disease After Allogeneic Stem Cell Transplantation. Tohoku J Exp Med. 2020;251:81-85.
13. Ureshino H, Shindo T, Sano H, Kubota Y, Ando T, Kidoguchi K, Kusaba K, Itamura H, Kojima H, Kusunoki Y, Miyazaki Y, Kojima K, Tanaka H, Saji H, Oshima K, Kimura S. Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2020;111:733-738.
14. Nakamura M, Iwasa H, Kojima K. Central nervous system involvement in mantle cell lymphoma presenting magnetic resonance imaging features of mild encephalitis/encephalopathy with a reversible splenial lesion. Intern Med. 2021;60:1597-1600.
15. Kondo T, Iguchi M, Yoshida S, Yoshino T, Kojima K. Cyclin D2-positive mantle cell lymphoma with t(2;12)(p12;p13) arising in immune deficiency/dysregulation. Ann Hematol 2023;102:2639-2640.
16. Eda H, Arakawa Y, Yoshida T, Ogasawara F, Kojima K, Nakaminami H, Yamagishi Y. Unilateral lymphadenitis caused by community-associated methicillin-resistant Staphylococcus aureus ST834 strain. J Infect Chemother. 2023:S1341-321X(23)00309-4.
17. Tsuge N, Ogasawara F, Kondo T, Yoshida S, Kojima K. A novel four-way translocation variant t(8;14;15;21)(q22;q22;q15;q22.1) in acute myeloid leukemia with RUNX1::RUNX1T1. Turk J Haematol 2024;41:128-129.
18. Kondo T, Ohara K, Yoshida S, Kojima K. Development of disseminated intravascular coagulation in asymptomatic leukemic non-nodal mantle cell lymphoma. Ann Hematol. 2024;103:3273-3275.
19. Yoshida S, Watanabe S, Ohara K, Iguchi M, Asagiri A, Umebara D, Kojima K. Autoimmune hemolytic anemia preceding one year before acute leukemic manifestation of lymphoma with a chronic lymphocytic leukemia immunophenotype. Int J Hematol, in press.
邦文総説（2019~）
1. 小島研介．分子標的治療時代の慢性リンパ性白血病治療戦略．臨床血液，2020; 61, 1275-1280.
2. 小島研介．TP53 変異骨髄異形成症候群/急性骨髄性白血病 (MDS/AML)の病態と臨床．臨床血液, 2023;64:955-961.
邦文症例報告（2019~. 抜粋）
1. 小笠原史也, 伊藤孟彦, 中村真, 佐伯恭昌, 谷口亜裕子, 砥谷和人, 小島研介．ステロイド治療中に後天性フィブリノゲン低下症をきたした白血病．臨床血液，2021;62:193-195.
2. 砥谷和人, 朝霧正, 上岡樹生, 小島研介．バリアントe13a3 (b2a3）BCR-ABL1慢性骨髄性白血病の良好なABL1チロシンキナーゼ阻害剤感受性．臨床血液，2021;62:180-185．
3. 砥谷和人, 江田雅志, 朝霧正, 小島研介．国内未承認の輸入サプリメントによる鉛中毒．臨床血液，2021;62:267-269．
4. 宮﨑詩織, 西田愛恵, 朝霧正, 重留一貴, 木田和伸, 久川浩章, 砥谷和人, 小島研介．APTT試薬による偽性APTT延長症．臨床血液, 2021;62:1515-1518．
5. 江田仁海，渡部伸一朗，小笠原史也，佐伯恭昌，吉田将平，砥谷和人，武内あか里，宮﨑詩織，小島研介. 健康診断で好中球減少を指摘された無症候性の早期急性前骨髄球性白血病〜末梢血WT1 mRNA測定の有用性．臨床血液, 2022;63:1520-1524．
6. 大原慶斗，津下典子，渡部伸一朗，江田仁海，小笠原史也，近藤匠，吉田将平，小島研介．Ferroportin diseaseにおける妊娠・出産時の鉄代謝管理．臨床血液（印刷中）．
7. 渡部伸一朗，中路康介，越智経浩，和田倫子，小笠原史也，吉田将平，小島研介．原発性胆汁性胆管炎に合併した肝原発びまん性大細胞型B細胞リンパ腫．臨床血液 2024;65:1480-1484.
邦文著書（2019~. 抜粋）
1. 小島研介．治療のプロトコール：慢性リンパ性白血病 (CLL)，白血病治療マニュアル（改訂第4版），清井仁・宮本敏浩編，pp. 161-168，南江堂，東京，2020.
2. 小島研介．：II. 造血器腫瘍の基礎：細胞周期（TP53含む），日本臨牀増刊号 造血器腫瘍学（第2版），柴山浩彦・金倉譲編，pp. 73-78，日本臨牀社，東京，2020.
3. 砥谷和人，小島研介．慢性リンパ性白血病に対する分子標的治療の進展，血液内科 (81)，pp. 455-461，科学評論社，東京，2020．
4. 小島研介．現在の標準治療：CLL/SLLに対する治療戦略，リンパ腫の診療update，日本臨牀 (79)，pp. 359–364，日本臨牀社，東京，2021.
5. 佐伯恭昌，小島研介．慢性リンパ性白血病，特集：大きく進歩した造血器腫瘍の診断と治療，診断と治療 (109), pp. 787–790，診断と治療社，東京，2021.
6. 小島研介．高知県の血液内科学 病理と処方箋．高知県医師会医学雑誌第26巻1号, pp. 264-269, 高知県医師会, 2021．
7. 小島研介．質疑応答 プロからプロへ：慢性リンパ性白血病の初回治療で免疫化学療法とBTK阻害剤の使い分けのポイント，日本医事新報 (5065), pp. 47-48, 日本医事新報社，2021．
8. 小島研介．慢性リンパ性白血病におけるBTK阻害薬とBCL2阻害薬選択の考え方と注意点，造血器腫瘍における新規薬剤選択の考え方と注意点，血液内科 (82), pp. 790-795，科学評論社，東京，2021.
9. 小島研介．質疑応答・プロからプロへ：同種移植後を含めた、急性骨髄性白血病に対するFLT3阻害薬の使い方（Ｑ）．日本医事新報 (5068), p. 49，日本医事新報社，東京，2021.
10. 小島研介．慢性リンパ性白血病におけるBCL2阻害薬の耐性機序，造血器腫瘍に対する分子標的薬の耐性機序，血液内科 (83), pp, 473-478，科学評論社，東京，2021.
11. 小島研介．慢性リンパ性白血病の薬剤耐性とその克服，慢性白血病 – 最新の診断と治療 –，日本臨牀 (79)，pp.1782-1787，日本臨牀社，東京，2021.
12. 小島研介．慢性リンパ性白血病，今日の治療指針 私はこう治療している2022年版，pp. 695–697，医学書院，東京，2022．
13. 小島研介．慢性リンパ性白血病，生涯教育シリーズ–102 血液疾患のすべて，日本医師会雑誌(151)，pp.256-257，日本医師会，東京，2022.
14. 小島研介．慢性リンパ性白血病に対する新規分子標的治療，造血器腫瘍に対する新規治療薬，腫瘍内科（29），pp, 427-431，科学評論社，東京，2021.
15. 小島研介．慢性リンパ性白血病のリスク評価と治療選択，層別化される悪性リンパ腫の病態と診療，血液内科（84），pp, 333-338，科学評論社，東京，2022.
16. 小島研介．初発 CLLの治療方針，EBM血液疾患の治療2023-2024，pp.238-242，中外医学社，東京，2022.
17. 小島研介．CLLセカンドライン治療におけるBTK阻害薬と BCL2阻害薬の使い分け，造血器腫瘍の治療開発におけるunanswered questions - エビデンスと今後の展望，血液内科（85），pp, 510-514，科学評論社，東京，2023.
18. 小島研介，高松泰．慢性リンパ性白血病，日本血液学会造血器腫瘍診療ガイドライン2023，pp. 147-172，金原出版，東京，2023.
19. 小島研介．CLLに対する今後の分子標的治療薬，EBM血液疾患の治療2025-2026，pp. 266-270，中外医学社，東京，2024.
20. 小島研介．【Chapter 3: ここまできた！白血病の治療】慢性リンパ性白血病，広く浅く知る白血病，臨床雑誌「内科」（134），pp. 898-901，南江堂，東京，2024.
21. 小島研介．慢性リンパ性白血病，今日の診断指針 第9版，pp. 1043–1046，医学書院，東京，2025.
22. 小島研介．リンパ系腫瘍の WHO分類，ICC分類 慢性リンパ性白血病，新・白血病学・上 ―病態・診断・治療―，日本臨牀2025年4月増刊号，pp.403-407，日本臨牀社，東京，2025.
23. 小島研介．慢性リンパ性白血病（CLL），血液疾患最新の治療2026-2028，pp. 138-140，南江堂，東京，2025. 24. 小島研介．分子標的治療薬（BTK阻害薬），特集 最近よく聞く他科の薬 先生の外来にこの薬を使っている患者さんがきますよ，臨床雑誌「内科」（136），pp.479-483，南江堂，東京，2025. 25. 吉田将平，小島研介．慢性リンパ性白血病に対する薬物療法選択の考え方，血液内科（91），pp.210-217，科学評論社，東京，2025.
1. Ureshino H, Kusaba K, Kidoguchi K, Sano H, Nishioka A, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Sueoka E, Kimura S. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma. Ann Hematol. 2019; 98:465-471.
2. Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, Nakao T, Kanda Y, Kosugi N, Kosugi H, Kumagai T, Harada H, Shikami M, Maeda Y, Sakura T, Inokuchi K, Saito A, Nawa Y, Ogasawara M, Nishida J, Kondo T, Yoshida C, Kuroda H, Tabe Y, Maeda Y, Imajo K, Kojima K, Morita S, Komukai S, Kawaguchi A, Sakamoto J, Kimura S. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int J Clin Oncol. 2019; 24:445-453.
3. Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell. 2019; 35:721-737.
4. Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, Allen JE, Oster W, Stogniew M, Ishizawa J, Andreeff M. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia. 2019;33:2805-2816.
5. Okamoto S, Ureshino H, Kidoguchi K, Kusaba K, Kizuka-Sano H, Sano H, Nishioka A, Yamaguchi K, Kamachi K, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Kawaguchi A, Sueoka E, Kimura S. Clinical impact of the CONUT score in patients with multiple myeloma. Ann Hematol. 2020;99:113-119.
6. Watanabe T, Yamashita S, Ureshino H, Kamachi K, Kurahashi Y, Fukuda-Kurahashi Y, Yoshida N, Hattori N, Nakamura H, Sato A, Kawaguchi A, Sueoka-Aragane N, Kojima K, Okada S, Ushijima T, Kimura S, Sueoka E. Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis using the new oral demethylating agent OR-2100. Blood. 2020; 36:871-884.
7. Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. Cancer Sci. 2021;112:1943-1954.
8. Nishida Y, Zhao R, Heese LE, Akiyama H, Patel S, Jaeger AM, Jacamo RO, Kojima K, Ma MCJ, Ruvolo VR, Chachad D, Devine W, Lindquist S, Davis RE, Porco JA Jr, Whitesell L, Andreeff M, Ishizawa J. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia 2021;35:2469-2481.
9. Nishimori T, Higuchi T, Hashida Y, Ujihara T, Taniguchi A, Ogasawara F, Kitamura N, Murakami I, Kojima K, Daibata M. Development of a novel cell line-derived xenograft model of primary herpesvirus 8-unrelated effusion large B-cell lymphoma and antitumor activity of birabresib in vitro and in vivo. Cancer Med. 2021;10:8976-8987.
10. Ogasawara F, Higuchi T, Nishimori T, Hashida Y, Kojima K, Daibata M. Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8-unrelated effusion large B-cell lymphoma in vivo. J Cell Mol Med. 2022;26:5580-5589.
11. Ogasawara F, Yoshida S, Yamane M, Takamatsu K, Arakawa Y, Nishida Y, Komatsu M, Yokoyama A, Yamagishi Y, Kojima K. COVID-19 Cluster in the Hematology/Respirology Ward of a University Hospital during the Seventh Wave of the SARS-CoV-2 Pandemic in Japan: A Descriptive Study. Intern Med. 2023 May 1;62(9):1265-1271.
12. Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Kojima K, Nakamura Y, Fukuhara S, Izutsu K, Abutani H, Yamauchi N, Yuda J, Minami Y; All HM-SCREEN-Japan 01 investigators. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. Cancer Sci. 2023 114:2098-2108.
13. Kurayoshi K, Takase Y, Ueno M, Ohta K, Fuse K, Ikeda S, Watanabe T, Nishida Y, Horike SI, Hosomichi K, Ishikawa Y, Tadokoro Y, Kobayashi M, Kasahara A, Jing Y, Shoulkamy MI, Meguro-Horike M, Kojima K, Kiyoi H, Sugiyama H, Nagase H, Tajima A, Hirao A. Targeting cis-regulatory elements of FOXO family is a novel therapeutic strategy for induction of leukemia cell differentiation. Cell Death Dis. 2023;14:642.
14. Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023;9(48):eadh1436.
15. Egawa Y, Higuchi T, Hashida Y, Ueno K, Kojima K, Daibata M*. Novel paired CD13-negative (MT-50.1) and CD13-positive (MT-50.4) HTLV-1-infected T-cell lines with differential regulatory T cell-like activity. Sci Rep. 2024;14:12549.
16. Kojima K, Watanabe S, Takeuchi A, Kunisawa N, Yoshida S. BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL. J Clin Exp Hematop. 2025;65:174-179.
17. Kojima K, Tsuge N, Yoshida S, Umebara D, Nishida Y, Miyazaki S, Asagiri T. Myelodysplastic neoplasms with unbalanced whole-arm translocation der(5;19)(p10;q10): association with double-hit TP53 mutations. Int J Hematol, in press.
18. Shah NN, Zinzani PL, Wang ML, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss BJ, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve M, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada PB, Cheah CY. Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study. Blood Adv, in press.
英文総説（2019~）
Kojima K, Burger JA. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. J Clin Exp Hematop. 2020; 60:130-137.
英文症例報告（2019~. 抜粋）
1. Kidoguchi K, Yoshimura M, Kojima K, Ureshino H, Egashira R, Yokoo M, Kai K, Egashira Y, Ohshima K, Ando T, Kimura S. Oral ulceration: an unusual manifestation of lymphomatoid granulomatosis. Ann Hematol. 2019;98:1305-1307.
2. Yokoo M, Kojima K, Sano H, Kai K, Arakawa F, Ohshima K, Matsunaga T, Kimura S. Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy. Ann Hematol. 2019;98:1501-1503.
3. Kidoguchi K, Kojima K, Seki R, Nagafuji K, Ohshima K, Kimura S. Is clinicopathological distinction of mucosa-associated lymphoid tissue lymphoma from Waldenström macroglobulinemia essential in MYD88 L265P mutation-positive cases? Int J Hematol. 2019;109:247-248.
4. Kamachi K, Kubota Y, Nagaie T, Yamaguchi Y, Ogusu S, Kidoguchi K, Kusaba K, Kizuka-Sano H, Nishioka A, Yoshimura M, Yokoo M, Ando T, Kai K, Kojima K, Ohshima K, Sueoka E, Kimura S. Primary chest wall MYC/BCL6 double-hit lymphoma with t(3;7)(q27;p12) and t(8;14)(q24;q32) translocations. Intern Med. 2019; 58:2073-2077.
5. Kidoguchi K, Kojima K, Yokoo M, Kimura S. BCR-ABL1- and CBFB-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis. Ann Hematol. 2019;98:2461-2462.
6. Kidoguchi K, Kubota Y, Kusaba K, Kizuka-Sano H, Yamaguchi K, Nishioka A, Yokoo M, Ando T, Kojima K, Kimura S. Severe infusion reaction, anti-rituximab antibodies and lymphoma. QJM. 2020;113:273-274.
7. Ogasawara F, Nakatani Y, Kojima K. Superior vena cava lymphoma. Intern Med. 2020;59:1231.
8. Fujita M, Kamachi K, Yokoo M, Kidoguchi K, Kusaba K, Kizuka-Sano H, Yamaguchi K, Nishioka A, Yoshimura M, Kubota Y, Ando T, Kojima K, Kimura S. Accelerated Phase of Atypical Chronic Myeloid Leukemia with Severe Disseminated Intravascular Coagulation at Initial Presentation. Intern Med. 2020;59:1549-1553.
9. Ando T, Sano H, Yokoo M, Kusaba K, Kidoguchi K, Yamaguchi K, Katsuya H, Yoshihara S, Kubota Y, Kojima K, Kimura S. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor. Int J Hematol. 2020;112:249-253.
10. Saeki K, Nakamura M, Kojima K. Primary pulmonary diffuse large B-cell lymphoma presenting as bulky bilateral lung tumors. Ann Hematol. 2021;100:577-578.
11. Nakamura M, Saeki K, Egashira R, Egashira Y, Kojima K. Gastric emphysema in chemosensitive gastric diffuse large B cell lymphoma. Ann Hematol. 2020;99:2457-2458.
12. Kamachi K, Ando T, Tsuruoka N, Hashiguchi M, Kidoguchi K, Kusaba K, Sano H, Yamaguchi K, Nishioka A, Yoshimura M, Yokoo M, Kubota Y, Kojima K, Kimura S. Successful Anti-TNF-alpha Therapy for Crohn's Disease After Allogeneic Stem Cell Transplantation. Tohoku J Exp Med. 2020;251:81-85.
13. Ureshino H, Shindo T, Sano H, Kubota Y, Ando T, Kidoguchi K, Kusaba K, Itamura H, Kojima H, Kusunoki Y, Miyazaki Y, Kojima K, Tanaka H, Saji H, Oshima K, Kimura S. Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2020;111:733-738.
14. Nakamura M, Iwasa H, Kojima K. Central nervous system involvement in mantle cell lymphoma presenting magnetic resonance imaging features of mild encephalitis/encephalopathy with a reversible splenial lesion. Intern Med. 2021;60:1597-1600.
15. Kondo T, Iguchi M, Yoshida S, Yoshino T, Kojima K. Cyclin D2-positive mantle cell lymphoma with t(2;12)(p12;p13) arising in immune deficiency/dysregulation. Ann Hematol 2023;102:2639-2640.
16. Eda H, Arakawa Y, Yoshida T, Ogasawara F, Kojima K, Nakaminami H, Yamagishi Y. Unilateral lymphadenitis caused by community-associated methicillin-resistant Staphylococcus aureus ST834 strain. J Infect Chemother. 2023:S1341-321X(23)00309-4.
17. Tsuge N, Ogasawara F, Kondo T, Yoshida S, Kojima K. A novel four-way translocation variant t(8;14;15;21)(q22;q22;q15;q22.1) in acute myeloid leukemia with RUNX1::RUNX1T1. Turk J Haematol 2024;41:128-129.
18. Kondo T, Ohara K, Yoshida S, Kojima K. Development of disseminated intravascular coagulation in asymptomatic leukemic non-nodal mantle cell lymphoma. Ann Hematol. 2024;103:3273-3275.
19. Yoshida S, Watanabe S, Ohara K, Iguchi M, Asagiri A, Umebara D, Kojima K. Autoimmune hemolytic anemia preceding one year before acute leukemic manifestation of lymphoma with a chronic lymphocytic leukemia immunophenotype. Int J Hematol, in press.
邦文総説（2019~）
1. 小島研介．分子標的治療時代の慢性リンパ性白血病治療戦略．臨床血液，2020; 61, 1275-1280.
2. 小島研介．TP53 変異骨髄異形成症候群/急性骨髄性白血病 (MDS/AML)の病態と臨床．臨床血液, 2023;64:955-961.
邦文症例報告（2019~. 抜粋）
1. 小笠原史也, 伊藤孟彦, 中村真, 佐伯恭昌, 谷口亜裕子, 砥谷和人, 小島研介．ステロイド治療中に後天性フィブリノゲン低下症をきたした白血病．臨床血液，2021;62:193-195.
2. 砥谷和人, 朝霧正, 上岡樹生, 小島研介．バリアントe13a3 (b2a3）BCR-ABL1慢性骨髄性白血病の良好なABL1チロシンキナーゼ阻害剤感受性．臨床血液，2021;62:180-185．
3. 砥谷和人, 江田雅志, 朝霧正, 小島研介．国内未承認の輸入サプリメントによる鉛中毒．臨床血液，2021;62:267-269．
4. 宮﨑詩織, 西田愛恵, 朝霧正, 重留一貴, 木田和伸, 久川浩章, 砥谷和人, 小島研介．APTT試薬による偽性APTT延長症．臨床血液, 2021;62:1515-1518．
5. 江田仁海，渡部伸一朗，小笠原史也，佐伯恭昌，吉田将平，砥谷和人，武内あか里，宮﨑詩織，小島研介. 健康診断で好中球減少を指摘された無症候性の早期急性前骨髄球性白血病〜末梢血WT1 mRNA測定の有用性．臨床血液, 2022;63:1520-1524．
6. 大原慶斗，津下典子，渡部伸一朗，江田仁海，小笠原史也，近藤匠，吉田将平，小島研介．Ferroportin diseaseにおける妊娠・出産時の鉄代謝管理．臨床血液（印刷中）．
7. 渡部伸一朗，中路康介，越智経浩，和田倫子，小笠原史也，吉田将平，小島研介．原発性胆汁性胆管炎に合併した肝原発びまん性大細胞型B細胞リンパ腫．臨床血液 2024;65:1480-1484.
邦文著書（2019~. 抜粋）
1. 小島研介．治療のプロトコール：慢性リンパ性白血病 (CLL)，白血病治療マニュアル（改訂第4版），清井仁・宮本敏浩編，pp. 161-168，南江堂，東京，2020.
2. 小島研介．：II. 造血器腫瘍の基礎：細胞周期（TP53含む），日本臨牀増刊号 造血器腫瘍学（第2版），柴山浩彦・金倉譲編，pp. 73-78，日本臨牀社，東京，2020.
3. 砥谷和人，小島研介．慢性リンパ性白血病に対する分子標的治療の進展，血液内科 (81)，pp. 455-461，科学評論社，東京，2020．
4. 小島研介．現在の標準治療：CLL/SLLに対する治療戦略，リンパ腫の診療update，日本臨牀 (79)，pp. 359–364，日本臨牀社，東京，2021.
5. 佐伯恭昌，小島研介．慢性リンパ性白血病，特集：大きく進歩した造血器腫瘍の診断と治療，診断と治療 (109), pp. 787–790，診断と治療社，東京，2021.
6. 小島研介．高知県の血液内科学 病理と処方箋．高知県医師会医学雑誌第26巻1号, pp. 264-269, 高知県医師会, 2021．
7. 小島研介．質疑応答 プロからプロへ：慢性リンパ性白血病の初回治療で免疫化学療法とBTK阻害剤の使い分けのポイント，日本医事新報 (5065), pp. 47-48, 日本医事新報社，2021．
8. 小島研介．慢性リンパ性白血病におけるBTK阻害薬とBCL2阻害薬選択の考え方と注意点，造血器腫瘍における新規薬剤選択の考え方と注意点，血液内科 (82), pp. 790-795，科学評論社，東京，2021.
9. 小島研介．質疑応答・プロからプロへ：同種移植後を含めた、急性骨髄性白血病に対するFLT3阻害薬の使い方（Ｑ）．日本医事新報 (5068), p. 49，日本医事新報社，東京，2021.
10. 小島研介．慢性リンパ性白血病におけるBCL2阻害薬の耐性機序，造血器腫瘍に対する分子標的薬の耐性機序，血液内科 (83), pp, 473-478，科学評論社，東京，2021.
11. 小島研介．慢性リンパ性白血病の薬剤耐性とその克服，慢性白血病 – 最新の診断と治療 –，日本臨牀 (79)，pp.1782-1787，日本臨牀社，東京，2021.
12. 小島研介．慢性リンパ性白血病，今日の治療指針 私はこう治療している2022年版，pp. 695–697，医学書院，東京，2022．
13. 小島研介．慢性リンパ性白血病，生涯教育シリーズ–102 血液疾患のすべて，日本医師会雑誌(151)，pp.256-257，日本医師会，東京，2022.
14. 小島研介．慢性リンパ性白血病に対する新規分子標的治療，造血器腫瘍に対する新規治療薬，腫瘍内科（29），pp, 427-431，科学評論社，東京，2021.
15. 小島研介．慢性リンパ性白血病のリスク評価と治療選択，層別化される悪性リンパ腫の病態と診療，血液内科（84），pp, 333-338，科学評論社，東京，2022.
16. 小島研介．初発 CLLの治療方針，EBM血液疾患の治療2023-2024，pp.238-242，中外医学社，東京，2022.
17. 小島研介．CLLセカンドライン治療におけるBTK阻害薬と BCL2阻害薬の使い分け，造血器腫瘍の治療開発におけるunanswered questions - エビデンスと今後の展望，血液内科（85），pp, 510-514，科学評論社，東京，2023.
18. 小島研介，高松泰．慢性リンパ性白血病，日本血液学会造血器腫瘍診療ガイドライン2023，pp. 147-172，金原出版，東京，2023.
19. 小島研介．CLLに対する今後の分子標的治療薬，EBM血液疾患の治療2025-2026，pp. 266-270，中外医学社，東京，2024.
20. 小島研介．【Chapter 3: ここまできた！白血病の治療】慢性リンパ性白血病，広く浅く知る白血病，臨床雑誌「内科」（134），pp. 898-901，南江堂，東京，2024.
21. 小島研介．慢性リンパ性白血病，今日の診断指針 第9版，pp. 1043–1046，医学書院，東京，2025.
22. 小島研介．リンパ系腫瘍の WHO分類，ICC分類 慢性リンパ性白血病，新・白血病学・上 ―病態・診断・治療―，日本臨牀2025年4月増刊号，pp.403-407，日本臨牀社，東京，2025.
23. 小島研介．慢性リンパ性白血病（CLL），血液疾患最新の治療2026-2028，pp. 138-140，南江堂，東京，2025. 24. 小島研介．分子標的治療薬（BTK阻害薬），特集 最近よく聞く他科の薬 先生の外来にこの薬を使っている患者さんがきますよ，臨床雑誌「内科」（136），pp.479-483，南江堂，東京，2025. 25. 吉田将平，小島研介．慢性リンパ性白血病に対する薬物療法選択の考え方，血液内科（91），pp.210-217，科学評論社，東京，2025.
.